Compare · GLP-1 agonist
Liraglutide vs Orforglipron
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Liraglutide | Orforglipron | |
|---|---|---|
| Evidence | Strong human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. |
| Full profile → | Full profile → |
Liraglutide
Liraglutide is one of the better-studied metabolic drugs of the last fifteen years, and the direct predecessor to semaglutide. Its two approved uses rest on large, replicated, double-blind randomized trials with hard endpoints, so the honest job here is to separate what the evidence firmly supports…
Orforglipron
Orforglipron (brand name Foundayo) is a GLP-1 receptor agonist — the same drug class as semaglutide and tirzepatide — but with one defining difference: it is a small molecule, not a peptide, and it is taken as a once-daily pill rather than an injection. In April 2026 the FDA approved it for chronic…